GRTX · As filed with the SEC
Galera Therapeutics cash flow statement, by fiscal year
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating activities: | ||||||||
| Net loss | 149,049,000 | (18,957,000) | (59,082,000) | (62,222,000) | (80,534,000) | (74,218,000) | (51,930,000) | (23,676,000) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||
| Depreciation | — | — | — | — | — | 368,000 | 267,000 | 127,000 |
| Acquired in-process research and development | 0 | 3,843,000 | — | — | — | — | — | — |
| Depreciation and amortization | 0 | 20,000 | 259,000 | 114,000 | 778,000 | — | — | — |
| Noncash interest expense | — | 0 | 11,414,000 | 11,571,000 | 7,194,000 | 4,880,000 | 3,031,000 | 220,000 |
| Share-based compensation expense | 410,000 | 2,545,000 | 5,560,000 | 7,164,000 | 7,231,000 | 5,536,000 | 2,390,000 | 865,000 |
| Reserve for tax incentive receivable | — | — | — | — | — | — | 241,000 | — |
| Deferred tax liability | — | — | — | — | 0 | (16,000) | (9,000) | (223,000) |
| Deferred rent | — | — | — | — | — | — | 4,000 | (2,000) |
| Write-off of acquired intangible asset | 0 | 2,258,000 | — | — | — | — | — | — |
| Write-off of goodwill | 0 | 881,000 | — | — | — | — | — | — |
| Deferred tax benefit | 0 | 203,000 | 0 | (70,000) | — | — | — | — |
| Change in fair value of warrants | (294,000) | (452,000) | — | — | — | — | — | — |
| Gain on sale of dismutase mimetics assets | (3,500,000) | — | — | — | — | — | — | — |
| Gain on extinguishment of debt | (151,049,000) | — | — | — | — | — | — | — |
| Loss on disposal of property and equipment | 0 | 48,000 | (72,000) | — | — | — | — | — |
| Tax incentive receivable | — | — | — | — | — | — | 629,000 | (363,000) |
| Refundable PDUFA fee | — | 0 | 3,242,000 | (3,242,000) | — | — | — | — |
| Prepaid expenses and other current assets | 357,000 | 2,295,000 | 514,000 | 2,529,000 | (1,022,000) | 127,000 | (3,815,000) | (986,000) |
| Other assets | (1,000) | 89,000 | 1,932,000 | 330,000 | (246,000) | (274,000) | (421,000) | (255,000) |
| Accounts payable | (1,010,000) | (1,416,000) | (2,206,000) | (1,463,000) | (101,000) | 1,201,000 | 77,000 | 1,587,000 |
| Accrued expenses | (11,000) | (3,058,000) | (6,305,000) | 2,121,000 | (951,000) | 2,859,000 | 2,875,000 | 540,000 |
| Other liabilities | 0 | (38,000) | (104,000) | (258,000) | (307,000) | — | — | — |
| Cash used in operating activities | (6,049,000) | (12,145,000) | (44,848,000) | (43,426,000) | (67,958,000) | (59,537,000) | (46,661,000) | (22,166,000) |
| Investing activities: | ||||||||
| Purchases of short-term investments | — | 0 | (22,643,000) | (59,891,000) | (71,979,000) | (67,746,000) | (123,192,000) | (71,190,000) |
| Proceeds from sales of short-term investments | — | 0 | 49,995,000 | 83,910,000 | 77,500,000 | 104,750,000 | 96,000,000 | 12,501,000 |
| Cash paid for acquisition of Nova | 0 | (50,000) | — | — | — | — | — | — |
| Purchase of property and equipment | — | 0 | (59,000) | (25,000) | (283,000) | (457,000) | (633,000) | (347,000) |
| Proceeds from sale of property and equipment | 0 | 4,000 | — | — | — | — | — | — |
| Proceeds from sale of dismutase mimetics asset | 3,500,000 | — | — | — | — | — | — | — |
| Cash provided by investing activities | 3,500,000 | (46,000) | 27,293,000 | 23,994,000 | 5,238,000 | 36,547,000 | (27,825,000) | (59,036,000) |
| Financing activities: | ||||||||
| Proceeds from royalty purchase agreement | — | — | — | 0 | 57,500,000 | 20,000,000 | 20,000,000 | 20,000,000 |
| Proceeds from the sale of Series C redeemable convertible preferred stock, net of issuance costs | — | — | — | — | — | — | — | 69,844,000 |
| Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs | 635,000 | 2,223,000 | — | — | — | — | — | — |
| Proceeds from the sale of common stock and common stock warrants in registered direct offering, net of issuance costs | — | 0 | 27,598,000 | — | — | — | — | — |
| Proceeds from the sale of common stock under the Open Market Sale Agreement, net of issuance costs | — | — | 1,701,000 | 3,808,000 | 7,941,000 | — | 58,021,000 | — |
| Proceeds from the exercise of common stock warrants | — | — | 2,009,000 | — | — | — | — | — |
| Proceeds from the sale of common stock under the Open Market Sale Agreement, net of issuance costs | — | 0 | — | — | — | — | — | — |
| Proceeds from the exercise of common stock warrants | — | 0 | — | — | — | — | — | — |
| Proceeds from exercise of stock options | — | 0 | 188,000 | 81,000 | 1,266,000 | 506,000 | 10,000 | — |
| Cash provided by financing activities | 635,000 | 2,223,000 | 31,496,000 | 3,889,000 | 66,707,000 | 20,506,000 | 78,031,000 | 89,844,000 |
| Net decrease in cash and cash equivalents | (1,914,000) | (9,968,000) | 13,941,000 | (15,543,000) | 3,987,000 | (2,484,000) | 3,545,000 | 8,642,000 |
| Cash and cash equivalents at beginning of year | 8,289,000 | 18,257,000 | 4,316,000 | 19,859,000 | 15,872,000 | 18,356,000 | 14,811,000 | 6,169,000 |
| Cash and cash equivalents at end of year | 6,375,000 | 8,289,000 | 18,257,000 | 4,316,000 | 19,859,000 | 15,872,000 | 18,356,000 | 14,811,000 |
| Supplemental schedule of non-cash investing and financing activities: | ||||||||
| Accretion of redeemable convertible preferred stock to redemption value | — | — | — | — | — | — | 7,178,000 | 5,910,000 |
| Issuance of warrants in conjunction with amendment to the Royalty Purchase Agreement | — | — | — | — | 0 | 4,712,000 | — | — |
| Deferred offering costs included in accounts payable and accrued expenses | — | — | — | — | 0 | 240,000 | — | — |
| Purchase of property and equipment included in accounts payable and accrued expenses | — | — | — | 0 | 9,000 | — | — | 23,000 |
| Conversion of redeemable convertible preferred stock into common stock | — | — | — | — | — | — | 173,080,000 | — |
| Initial recognition of operating lease right-of-use asset and operating lease liability | — | — | — | — | — | — | 1,084,000 | — |
| Extinguishment of royalty purchase liability upon sale of dismutase mimetics assets | 151,049,000 | — | — | — | — | — | — | — |
| Issuance of Series B redeemable convertible preferred stock in asset acquisition | 0 | 2,577,000 | — | — | — | — | — | — |
| Accretion (amortization) of redeemable convertible preferred stock to redemption value | (1,795,000) | 1,795,000 | — | — | — | — | — | — |
| Subscription receivable in connection with private placement | 0 | 635,000 | — | — | — | — | — | — |
| Derecognition of lease liability and right-of-use asset due to lease termination | 0 | 1,212,000 | — | — | — | — | — | — |
| Acquisition costs in accounts payable | 0 | 869,000 | — | — | — | — | — | — |
| Right-of-use asset obtained in exchange for lease obligation | — | 0 | 1,310,000 | — | — | — | — | — |
| Sale of property and equipment in exchange for prepaid future services | — | 0 | 240,000 | — | — | — | — | — |
| Reclassification of warrant liability to additional paid-in capital | 761,000 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.